¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"glucose level"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • sensorineural acuity level
    »ÀÀüµµÃ»·ÂÁ¤¹Ð¹®Åΰª, °ñÀüµµÃ»·ÂÁ¤¹Ð¿ªÄ¡
  • uncomfortable loudness level
    ºÒÄè¼Ò¸®¹®Åΰª, ºÒÄèÀ½¿ªÄ¡
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • speech interference level
    ȸȭ¹æÇØÄ¡
  • steady-state level
    Ç×Á¤»óżöÁØ
  • trace anesthetic level
    ÈçÀû¸¶ÃëÁ¦³óµµ
  • trough level
    ÃÖÀúÄ¡
  • uncomfortable loudness level
    ºÒÄèÀ½¿ªÄ¡
  • noise level meter
    ¼ÒÀ½°è
  • sound level meter
    ¼ÒÀ½°è, À½¾ÐÃøÁ¤±â
  • one step high level resistance
    ÀÏȸ°íÀúÇ×ȹµæ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • glucose-6-phosphatase
    ±Û·çÄÚ¿À½º-6-Æ÷½ºÆÄŸÁ¦
  • glucose-6-phosphate dehydrogenase
    ±Û·çÄÚ¿À½º-6-ÀλêÅ»¼ö¼ÒÈ¿¼Ò
  • glucose-6-phosphate dehydrogenase
    ±Û·çÄÚ½º-6-ÀλêµðÇÏÀ̵å·ÎÀú³×À̽º
  • glucose-6-phosphate dehydrogenase deficiency
    ±Û·çÄÚ½º-6-ÀλêµðÇÏÀÌ µå·ÎÀú³×À̽º °áÇÌ(Áõ)
  • glucose-cysteine agar
    ±Û·çÄÚ¿À½º-½Ã½ºÅ×ÀÎ
  • glucose-galactose
    ±Û·çÄÚ¿À½º-°¥¶ôÅ佺
  • glucose-galactose malabsorption
    ±Û·çÄÚ¿À½º-°¥¶ôÅ佺Èí¼öÀå¾Ö
  • random plasma glucose test
    ÀÓÀÇ(Àû)Ç÷Àå´ç½ÃÇè
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • liquid glucose
    ¾×ü±Û·çÄÚ½º.
  • non-glucose mellituria
    ºñÆ÷µµ´ç´¢¼º ´ç´¢
  • oral glucose tolerance test =OGTT
    °æ±¸Æ÷µµ´çºÎÇϽÃÇè.
  • oxidase-positive glucose fermenter
    »êÈ­È¿¼Ò¾ç¼º Æ÷µµ´ç¹ßÈ¿(Û£ý£)ü
  • random plasma glucose test
    ÀÓÀÇ(Àû)Ç÷Àå´ç½ÃÇè
  • transport maximum of glucose
    Æ÷µµ´ç(øãÔ¬ÓØ)À̵¿ÃÖ°íÄ¡.
  • uridine diphosphate glucose
    ÀÌÀλê¿ì¸®µò±Û·çÄÚ½º.
  • uridine diphosphate glucose-4-epimerase deficiency
    ¿ì¸®µòÀÌÀλê±Û·çÄÚ½º-4-¿¡ÇǸ޶óÁ¦°áÇÌ
  • urinary glucose
    ¿äÆ÷µµ´ç
  • urinary glucose test
    ¿äÆ÷µµ´ç½ÃÇè
  • acceptable noise level
    Çã¿ë¼ÒÀ½
  • air fluid level
    °ø±â ¾×üÃþ
  • alertness level
    °æ°è±âÁØ(ÌíÌüÐññÞ).
  • antimicrobial level
    Ç×±ÕÁ¦Ä¡<¼öÁØ(â©ñÞ)>
  • audiometric level
    û·Â, û·Â·¹º§
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
BOLD bleomycin, Oncovin, lomustin, dacarbazine; blood oxygenation level dependent
BSL benign symmetric lipomatosis; blood sugar level
CPDL cumulative population doubling level
CPL caprine placental lactogen; conditioned pitch level; congenital pulmonary lymphangiectasia
DL danger list; De Lee [catheter]; deep lobe; developmental level; difference limen; diffusion lung [ca...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
HLGR High Level Gentamicin Resistance
HLR High-level resistance
ILD interaural level difference
LDL Loudness Discomfort Level
LLLT Low Level Laser Therapy
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
glucose-6-dehydrogenase deficiency <biochemistry> An inherited condition that results in a deficiency in glucose-6-phosphate dehydrogenase. Particular drugs (sulphonamides) can exacerbate this problem. The result is haemolytic anaemia.
(27 Sep 1997)
glucose-6-phosphatase <enzyme> An enzyme that catalyses the conversion of d-glucose-6-phosphate and water to d-glucose and orthophosphate. This enzyme is deficient in glycogen storage disease Ia.
Chemical name: D-Glucose-6-phosphate phosphohydrolase
Registry number: EC 3.1.3.9
(12 Dec 1998)
glucose-6-phosphatase hepatorenal glycogenosis Glycogenosis due to glucose-6-phosphatase deficiency, resulting in accumulation of excessive amounts of glycogen of normal chemical structure, particularly in liver and kidney.
Synonym: Gierke's disease, glucose-6-phosphatase hepatorenal glycogenosis, von Gierke's disease.
(05 Mar 2000)
glucose-6-phosphate <biochemistry> Glucose 6-phosphate is a phosphomonoester of glucose that is formed by transfer of phosphate from ATP, catalysed by the enzyme hexokinase.
It is an intermediate both of the glycolytic pathway (next converted to fructose 6 phosphate) and of the NADPH generating pentose phosphate pathway, formed from glucose via hexokinase. However it is not strictly a glycolytic intermediate and it is readily converted to glycogen or oxidized to NADPH.
(10 Oct 1997)
glucose-6-phosphate dehydrogenase <enzyme> An NADP+ enzyme that catalyses the dehydrogenation (oxidation) of d-glucose-6-phosphate to 6-phospho-d-glucono-d-lactone, this reaction initiating the Dickens shunt.
Deficiency of this enzyme is the commonest disease-causing enzyme defect in humans affecting an estimated 400 million people.
The gene for this enzyme is on the X chromosome. Males with the enzyme deficiency develop haemolytic anaemia when red blood cells are exposed to oxidant drugs such as the antimalarial primaquine, the sulfonamide antibiotics or sulfones, naphthalene moth balls, or fava beans.
Synonym: Robison ester dehydrogenase, Zwischenferment.
Acronym: G6PD
(12 Sep 2002)
glucose-6-phosphate dehydrogenase deficiency A deficiency of glucose-6-phosphate dehydrogenase, an enzyme important for maintaining cellular concentrations of reduced nucleotides.
Deficiency of this enzyme is the commonest disease-causing enzyme defect in humans affecting an estimated 400 million people.
The gene for this enzyme is on the X chromosome and there are various polymorphic forms.
Males with the enzyme deficiency develop haemolytic anaemia when red blood cells are exposed to oxidant drugs such as the antimalarial primaquine, the sulfonamide antibiotics or sulfones, naphthalene moth balls, or fava beans. It can also cause anaemia of the newborn, and chronic nonspherocytic haemolytic anaemia.
Inheritance: X-linked.
(12 Sep 2002)
glucose-6-phosphate isomerase <enzyme> An enzyme that catalyses the reversible interconversion of glucose-6-phosphate and fructose-6-phosphate, and is a part of the glycolytic and gluconeogenic pathways. Deficiency of the enzyme, an autosomal recessive trait, results in liver glycogenesis and haemolytic anaemia.
Chemical name: D-Glucose-6-phosphate ketol-isomerase
Registry number: EC 5.3.1.9
(12 Dec 1998)
glucose-6-phosphate translocase <enzyme> A component of EC 3.1.3.9 which transports glucose phosphate into endoplasmic reticulum
Registry number: EC 2.7.-
Synonym: t1 transport protein
(26 Jun 1999)
glucose clamp technique <technique> Maintenance of a constant blood glucose level by perfusion or infusion with glucose or insulin. It is used for the study of metabolic rates (e.g., in glucose, lipid, amino acid metabolism) at constant glucose concentration.
(12 Dec 1998)
glucose dehydrogenase <enzyme> Converts beta-d-glucose to d-glucono-d-lactone, transferring hydrogen to NAD+ or NADP+.
Compare: glucose oxidase.
(05 Mar 2000)
glucose dehydrogenases <enzyme> D-glucose:1-oxidoreductases. Catalyses the oxidation of d-glucose to d-glucono-gamma-lactone and reduced acceptor. Any acceptor except molecular oxygen is permitted.
Registry number: EC 1.1.1.
(12 Dec 1998)
glucose effect <biochemistry> The ability of the sugar glucose to block sugar metabolism by keeping the genes which make the enzymes involved in the early steps of sugar metabolism from making those enzymes.
(09 Oct 1997)
glucose-fructose oxidoreductase <enzyme> Isolated from zymomonas mobilis; catalyses the formation of sorbitol and glucono-delta-lactone from glucose and fructose; enzyme contains tightly bound nadp+
Registry number: EC 1.1.99.-
(26 Jun 1999)
glucose intolerance A pathological state in which the fasting plasma glucose level is less than 140 mg per deciliter and the 30-, 60-, or 90-minute plasma glucose concentration following a glucose tolerance test exceeds 200 mg per deciliter. This condition is seen frequently in diabetes mellitus but also occurs with other diseases.
(12 Dec 1998)
glucose isomerase <enzyme> An isomerase enzyme which converts the sugar glucose into the sugar fructose. Fructose is a structural isomer of glucose.
(09 Oct 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á